One patient (patient 5) received a higher dose of IL-10-DLI (3 × 105 CD3+ T cells/kg), which led to rapid immune reconstitution, but the patient developed severe GvHD unresponsive to treatment and died 1 year post-HSCT because of recurrent infections related to IS therapy (Figure 1; Table 1). This evidence concerns the gene IL10 and graft versus host disease.